These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 33139244)

  • 21. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.
    Budczies J; Kazdal D; Allgäuer M; Christopoulos P; Rempel E; Pfarr N; Weichert W; Fröhling S; Thomas M; Peters S; Endris V; Schirmacher P; Stenzinger A
    Lung Cancer; 2020 Apr; 142():114-119. PubMed ID: 32143116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
    Vega DM; Yee LM; McShane LM; Williams PM; Chen L; Vilimas T; Fabrizio D; Funari V; Newberg J; Bruce LK; Chen SJ; Baden J; Carl Barrett J; Beer P; Butler M; Cheng JH; Conroy J; Cyanam D; Eyring K; Garcia E; Green G; Gregersen VR; Hellmann MD; Keefer LA; Lasiter L; Lazar AJ; Li MC; MacConaill LE; Meier K; Mellert H; Pabla S; Pallavajjalla A; Pestano G; Salgado R; Samara R; Sokol ES; Stafford P; Budczies J; Stenzinger A; Tom W; Valkenburg KC; Wang XZ; Weigman V; Xie M; Xie Q; Zehir A; Zhao C; Zhao Y; Stewart MD; Allen J;
    Ann Oncol; 2021 Dec; 32(12):1626-1636. PubMed ID: 34606929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement.
    Bailey NG
    Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour mutational burden: clinical utility, challenges and emerging improvements.
    Budczies J; Kazdal D; Menzel M; Beck S; Kluck K; Altbürger C; Schwab C; Allgäuer M; Ahadova A; Kloor M; Schirmacher P; Peters S; Krämer A; Christopoulos P; Stenzinger A
    Nat Rev Clin Oncol; 2024 Oct; 21(10):725-742. PubMed ID: 39192001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES).
    Yu L; Zhang Y; Wang D; Li L; Zhang R; Li J
    Am J Clin Pathol; 2024 Oct; 162(4):408-419. PubMed ID: 38733635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
    Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
    Nassar AH; Adib E; Abou Alaiwi S; El Zarif T; Groha S; Akl EW; Nuzzo PV; Mouhieddine TH; Perea-Chamblee T; Taraszka K; El-Khoury H; Labban M; Fong C; Arora KS; Labaki C; Xu W; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Zaitlen N; Schoenfeld AJ; Schultz N; Berger MF; MacConaill LE; Ananda G; Kwiatkowski DJ; Choueiri TK; Schrag D; Carrot-Zhang J; Gusev A
    Cancer Cell; 2022 Oct; 40(10):1161-1172.e5. PubMed ID: 36179682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    Stenzinger A; Endris V; Budczies J; Merkelbach-Bruse S; Kazdal D; Dietmaier W; Pfarr N; Siebolts U; Hummel M; Herold S; Andreas J; Zoche M; Tögel L; Rempel E; Maas J; Merino D; Stewart M; Zaoui K; Schlesner M; Glimm H; Fröhling S; Allen J; Horst D; Baretton G; Wickenhauser C; Tiemann M; Evert M; Moch H; Kirchner T; Büttner R; Schirmacher P; Jung A; Haller F; Weichert W; Dietel M
    J Thorac Oncol; 2020 Jul; 15(7):1177-1189. PubMed ID: 32119917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
    Wei B; Kang J; Kibukawa M; Arreaza G; Maguire M; Chen L; Qiu P; Lang L; Aurora-Garg D; Cristescu R; Levitan D
    J Mol Diagn; 2022 Jun; 24(6):600-608. PubMed ID: 35218944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.
    Wang X; Lamberti G; Di Federico A; Alessi J; Ferrara R; Sholl ML; Awad MM; Vokes N; Ricciuti B
    Ann Oncol; 2024 Jun; 35(6):508-522. PubMed ID: 38537779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing.
    Anaya J; Sidhom JW; Cummings CA; Baras AS;
    Cancer Res Commun; 2023 Mar; 3(3):501-509. PubMed ID: 36999044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
    Marcus L; Fashoyin-Aje LA; Donoghue M; Yuan M; Rodriguez L; Gallagher PS; Philip R; Ghosh S; Theoret MR; Beaver JA; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Sep; 27(17):4685-4689. PubMed ID: 34083238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.
    Barroso-Sousa R; Pacífico JP; Sammons S; Tolaney SM
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.